Guardant Health - GH Stock Forecast, Price & News

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GH shares.
View GH analyst ratings or view top-rated stocks.

13 brokerages have issued 1 year price targets for Guardant Health's stock. Their GH share price forecasts range from $33.00 to $88.00. On average, they expect the company's share price to reach $57.64 in the next twelve months. This suggests a possible upside of 136.9% from the stock's current price.
View analysts price targets for GH or view top-rated stocks among Wall Street analysts.

Guardant Health's stock was trading at $27.20 at the beginning of the year. Since then, GH stock has decreased by 10.6% and is now trading at $24.33.
View the best growth stocks for 2023 here.

Guardant Health saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 6,310,000 shares, a decline of 9.9% from the February 28th total of 7,000,000 shares. Based on an average daily trading volume, of 2,060,000 shares, the days-to-cover ratio is currently 3.1 days. Currently, 6.5% of the company's stock are short sold.
View Guardant Health's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our GH earnings forecast.

Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.90) by $0.16. The business had revenue of $94.80 million for the quarter, compared to analysts' expectations of $92.59 million. Guardant Health had a negative trailing twelve-month return on equity of 242.65% and a negative net margin of 145.61%. Guardant Health's quarterly revenue was up 26.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.78) EPS.

ETFs with the largest weight of Guardant Health (NASDAQ:GH) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Genomic Revolution ETF (ARKG), iShares U.S. Healthcare Providers ETF (IHF), Goldman Sachs Future Consumer Equity ETF (GBUY), Global X Founder-Run Companies ETF (BOSS) and Franklin Genomic Advancements ETF (HELX).

Guardant Health issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $525.00 million-$540.00 million, compared to the consensus revenue estimate of $554.00 million.

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

(GH) raised $200 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Guardant Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Clearbridge Investments LLC (2.53%), Alliancebernstein L.P. (2.46%), Price T Rowe Associates Inc. MD (1.66%), Geode Capital Management LLC (1.39%), Voya Investment Management LLC (1.34%) and Norges Bank (0.77%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends.

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GH stock can currently be purchased for approximately $24.33.

Guardant Health (NASDAQ:GH) has a market capitalization of $2.50 billion and generates $449.54 million in revenue each year. The company earns $-654,590,000.00 in net income (profit) each year or ($6.40) on an earnings per share basis.

The company employs 1,793 workers across the globe.

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.